vs
DELUXE CORP（DLX）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是DELUXE CORP的1.4倍（$772.1M vs $535.2M），Revvity净利率更高（12.7% vs 2.2%，领先10.5%），Revvity同比增速更快（5.9% vs 2.8%），过去两年Revvity的营收复合增速更高（9.0% vs 0.0%）
德朗士公司是一家美国企业，提供支付处理、数据服务、票据与促销产品以及商户服务，业务分为B2B支付、数据、印刷和商户服务四大板块。截至2025年，公司为数百万中小企业和数千家金融机构提供服务，每年处理支付交易总额超2.8万亿美元，虽传统核心业务为票据印刷等印刷产品，如今支付与数据服务已成为核心板块。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
DLX vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.4倍
$535.2M
营收增速更快
RVTY
高出3.0%
2.8%
净利率更高
RVTY
高出10.5%
2.2%
两年增速更快
RVTY
近两年复合增速
0.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $535.2M | $772.1M |
| 净利润 | $12.0M | $98.4M |
| 毛利率 | 52.2% | — |
| 营业利润率 | 8.9% | 14.5% |
| 净利率 | 2.2% | 12.7% |
| 营收同比 | 2.8% | 5.9% |
| 净利润同比 | -5.0% | 3.9% |
| 每股收益（稀释后） | $0.25 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DLXRVTY
| Q4 25 | $535.2M | $772.1M | ||
| Q3 25 | $540.2M | $698.9M | ||
| Q2 25 | $521.3M | $720.3M | ||
| Q1 25 | $536.5M | $664.8M | ||
| Q4 24 | $520.6M | $729.4M | ||
| Q3 24 | $528.4M | $684.0M | ||
| Q2 24 | $537.8M | $691.7M | ||
| Q1 24 | $535.0M | $649.9M |
净利润DLXRVTY
| Q4 25 | $12.0M | $98.4M | ||
| Q3 25 | $33.7M | $46.7M | ||
| Q2 25 | $22.4M | $53.9M | ||
| Q1 25 | $14.0M | $42.2M | ||
| Q4 24 | $12.6M | $94.6M | ||
| Q3 24 | $8.9M | $94.4M | ||
| Q2 24 | $20.5M | $55.4M | ||
| Q1 24 | $10.8M | $26.0M |
毛利率DLXRVTY
| Q4 25 | 52.2% | — | ||
| Q3 25 | 53.9% | 53.6% | ||
| Q2 25 | 53.6% | 54.5% | ||
| Q1 25 | 52.4% | 56.5% | ||
| Q4 24 | 52.3% | — | ||
| Q3 24 | 53.3% | 56.3% | ||
| Q2 24 | 53.7% | 55.7% | ||
| Q1 24 | 53.0% | 54.6% |
营业利润率DLXRVTY
| Q4 25 | 8.9% | 14.5% | ||
| Q3 25 | 14.0% | 11.7% | ||
| Q2 25 | 11.7% | 12.6% | ||
| Q1 25 | 9.0% | 10.9% | ||
| Q4 24 | 9.0% | 16.3% | ||
| Q3 24 | 7.9% | 14.3% | ||
| Q2 24 | 11.0% | 12.4% | ||
| Q1 24 | 8.3% | 6.8% |
净利率DLXRVTY
| Q4 25 | 2.2% | 12.7% | ||
| Q3 25 | 6.2% | 6.7% | ||
| Q2 25 | 4.3% | 7.5% | ||
| Q1 25 | 2.6% | 6.4% | ||
| Q4 24 | 2.4% | 13.0% | ||
| Q3 24 | 1.7% | 13.8% | ||
| Q2 24 | 3.8% | 8.0% | ||
| Q1 24 | 2.0% | 4.0% |
每股收益（稀释后）DLXRVTY
| Q4 25 | $0.25 | $0.86 | ||
| Q3 25 | $0.74 | $0.40 | ||
| Q2 25 | $0.50 | $0.46 | ||
| Q1 25 | $0.31 | $0.35 | ||
| Q4 24 | $0.28 | $0.77 | ||
| Q3 24 | $0.20 | $0.77 | ||
| Q2 24 | $0.46 | $0.45 | ||
| Q1 24 | $0.24 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $36.9M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $680.7M | $7.3B |
| 总资产 | $2.9B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DLXRVTY
| Q4 25 | $36.9M | $919.9M | ||
| Q3 25 | $25.8M | $931.4M | ||
| Q2 25 | $26.0M | $991.8M | ||
| Q1 25 | $30.3M | $1.1B | ||
| Q4 24 | $34.4M | $1.2B | ||
| Q3 24 | $41.3M | $1.2B | ||
| Q2 24 | $23.1M | $2.0B | ||
| Q1 24 | $23.5M | $1.7B |
股东权益DLXRVTY
| Q4 25 | $680.7M | $7.3B | ||
| Q3 25 | $664.1M | $7.4B | ||
| Q2 25 | $638.7M | $7.6B | ||
| Q1 25 | $622.5M | $7.6B | ||
| Q4 24 | $620.9M | $7.7B | ||
| Q3 24 | $612.7M | $7.9B | ||
| Q2 24 | $620.5M | $7.9B | ||
| Q1 24 | $608.4M | $7.8B |
总资产DLXRVTY
| Q4 25 | $2.9B | $12.2B | ||
| Q3 25 | $2.6B | $12.1B | ||
| Q2 25 | $2.5B | $12.4B | ||
| Q1 25 | $2.6B | $12.4B | ||
| Q4 24 | $2.8B | $12.4B | ||
| Q3 24 | $2.6B | $12.8B | ||
| Q2 24 | $2.7B | $13.4B | ||
| Q1 24 | $2.7B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $102.1M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 8.53× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流DLXRVTY
| Q4 25 | $102.1M | $182.0M | ||
| Q3 25 | $67.1M | $138.5M | ||
| Q2 25 | $51.1M | $134.3M | ||
| Q1 25 | $50.3M | $128.2M | ||
| Q4 24 | $60.2M | $174.2M | ||
| Q3 24 | $67.9M | $147.9M | ||
| Q2 24 | $39.6M | $158.6M | ||
| Q1 24 | $26.6M | $147.6M |
自由现金流DLXRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | $27.8M | $115.5M | ||
| Q1 25 | $24.3M | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | $46.7M | $125.6M | ||
| Q2 24 | $11.4M | $136.6M | ||
| Q1 24 | $6.1M | $129.7M |
自由现金流率DLXRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | 5.3% | 16.0% | ||
| Q1 25 | 4.5% | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | 8.8% | 18.4% | ||
| Q2 24 | 2.1% | 19.7% | ||
| Q1 24 | 1.1% | 20.0% |
资本支出强度DLXRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | 4.5% | 2.6% | ||
| Q1 25 | 4.8% | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | 4.0% | 3.3% | ||
| Q2 24 | 5.2% | 3.2% | ||
| Q1 24 | 3.8% | 2.7% |
现金转化率DLXRVTY
| Q4 25 | 8.53× | 1.85× | ||
| Q3 25 | 1.99× | 2.97× | ||
| Q2 25 | 2.28× | 2.49× | ||
| Q1 25 | 3.59× | 3.03× | ||
| Q4 24 | 4.77× | 1.84× | ||
| Q3 24 | 7.60× | 1.57× | ||
| Q2 24 | 1.94× | 2.87× | ||
| Q1 24 | 2.46× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DLX
| Services | $247.9M | 46% |
| B2B Payments | $76.3M | 14% |
| Datadrivenmarketingsolutions | $68.5M | 13% |
| Promotional Solutions Revenue | $60.9M | 11% |
| Treasurymanagementsolutions | $59.8M | 11% |
| Other | $17.3M | 3% |
| Other Web Based Solutions | $4.6M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
